A5028671796- Venous Thromboembolism Diagnosis and Management
- Blood Coagulation and Thrombosis Mechanisms
- Atrial Fibrillation Management and Outcomes
- Liver Disease and Transplantation
- Liver Disease Diagnosis and Treatment
- Hemophilia Treatment and Research
- Platelet Disorders and Treatments
- Clinical Laboratory Practices and Quality Control
- Systemic Lupus Erythematosus Research
- Heparin-Induced Thrombocytopenia and Thrombosis
- Trauma, Hemostasis, Coagulopathy, Resuscitation
- Hemodynamic Monitoring and Therapy
- Antiplatelet Therapy and Cardiovascular Diseases
- Cardiac Arrhythmias and Treatments
- Coagulation, Bradykinin, Polyphosphates, and Angioedema
- Vitamin K Research Studies
- Blood properties and coagulation
- Acute Myocardial Infarction Research
- Monoclonal and Polyclonal Antibodies Research
- Blood Pressure and Hypertension Studies
- Drug-Induced Hepatotoxicity and Protection
- Hepatitis C virus research
- Health Systems, Economic Evaluations, Quality of Life
- Hemoglobinopathies and Related Disorders
- Pancreatitis Pathology and Treatment
Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico
2016-2025
Ospedale Maggiore
2013-2024
Istituti di Ricovero e Cura a Carattere Scientifico
1996-2024
Mylan (Switzerland)
1983-2024
Luigi Einaudi Foundation
2018-2023
Ospedale L. Bonomo
2007-2021
University of Milan
2011-2020
Hudson Institute
2020
John Wiley & Sons (United States)
2020
University of Dundee
2018
The role played by coagulation defects in the occurrence of bleeding cirrhosis is still unclear. This partly due to lack tests that truly reflect balance procoagulant and anticoagulant factors vivo. Conventional such as prothrombin time activated partial thromboplastin are inadequate explore physiological mechanism regulating thrombin, because they do not allow full activation main factor, protein C, whose levels considerably reduced cirrhosis. We used a thrombin generation test investigate...
The optimal duration of oral anticoagulation in patients with idiopathic venous thromboembolism is uncertain. Testing D-dimer levels may play a role the assessment need for prolonged anticoagulation.We performed testing 1 month after discontinuation first unprovoked proximal deep-vein thrombosis or pulmonary embolism who had received vitamin K antagonist at least 3 months. Patients normal level did not resume anticoagulation, whereas those an abnormal were randomly assigned either to...
Normal coagulation has classically been conceptualized as a Y-shaped pathway, with distinct "intrinsic" and "extrinsic" components initiated by factor XII or VIIa/tissue factor, respectively, converging in "common" pathway at the level of FXa/FVa (prothrombinase) complex. Until recently, lack an established alternative concept hemostasis meant that most physicians view "cascade" model physiology. This reinforced fact screening tests (APTT, prothrombin time--INR) are often used though they...
Coagulation factor defects, thrombocytopenia, and thrombocytopathy are associated with cirrhosis. However, bleeding in patients who have cirrhosis does not entirely correlate abnormal coagulation tests. Recently, it was shown that because of the concomitant abnormalities procoagulant anticoagulant drives, thrombin generation plasma is normal when assessed assays include thrombomodulin (the main protein C activator). also generated vivo as a function platelets, suggesting thrombocytopenia...
The model for end-stage-liver-disease (MELD) is a mathematical score used to prioritize patients liver transplantation and includes results creatinine, bilirubin, prothrombin time (PT) expressed as international normalized ratio (INR). rationale of using the MELD rests on assumption that would be same across country if methods measure variables yield numerical regardless testing laboratory. Evidence was provided specific methodologies may influence MELD, PT-INR identified most important....